Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. (Nasdaq: CUE) on March 12, 2025, reporting events that occurred on March 10, 2025. The filing addresses corporate governance changes specifically regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Pasha Sarraf to the Board of Directors. This appointment was made following the recommendation of the Corporate Governance and Nominating Committee. No other material changes to the company's operations or financial status are disclosed in this document.
Compensation and Governance Details
- Appointment: Pasha Sarraf was appointed to the Board on March 10, 2025.
- Equity Grant: Upon appointment, Mr. Sarraf was granted an option to purchase 48,800 shares of common stock.
- Vesting Schedule: The option vests over three years, with one-third vesting on the one-year anniversary of the grant date and the remainder vesting in eight equal quarterly installments.
- Indemnification: Mr. Sarraf entered into a standard indemnification agreement, potentially requiring the Company to cover legal expenses, judgments, and penalties arising from his service as a director.
- Compensation Policy: Service compensation aligns with the Company's Director Compensation Policy, previously filed in the 10-Q for the period ended September 30, 2024.
Investor Verification Checklist
- Verify the full text of the Director Compensation Policy referenced in the 10-Q filed on November 14, 2024.
- Review the standard form of indemnification agreement to be filed in the upcoming 10-K for the year ended December 31, 2024.
- Confirm the absence of any undisclosed arrangements or understandings regarding Mr. Sarraf's selection as stated in the filing.
- Monitor future filings for the vesting schedule execution and any potential dilution from the 48,800 share option grant.